Elderly colorectal cancer patients are under treated

European Journal of Cancer, Supplement

Volumn 2, Issue 7, 2004, Pages 8-13

  Rougier, P ^a   Mitry, E ^a   Aranda, E ^b   Daniele, B ^c   Labianca, R ^d   Carrato, A ^e  

^a HÔPITAL AMBROISE PARÉ   (France)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c G RUMMO HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Colorectal cancer; Comprehensive geriatric assessment; CPT 11; Elderly; Irinotecan

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

AGE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW;

EID: 2642550590     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.04.009     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94:2001;153-156
2. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418
3. Simmonds P.C. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 321:2000;531-535
4. Kohne C.H., Grothey A., Bokemeyer C., Bontke N., Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann. Oncol. 12:2001;435-442
5. Popescu R.A., Norman A., Ross P.J., Parikh B., Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 17:1999;2412-2418
6. Kerr D.J., Gray R., McConkey C., Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules-less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann. Oncol. 11:2000;947-955
7. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 345:2001;1091-1097
8. Iwashyna T.J., Lamont E.B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J. Clin. Oncol. 20:2002;3992-3998
9. Neugut A.I., Fleischauer A.T., Sundararajan V., et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J. Clin. Oncol. 20:2002;2643-2650
10. Magne N., Francois E., Broisin L., et al. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am. J. Clin. Oncol. 25:2002;126-130
11. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 5:2000;224-237
12. Chen H., Cantor A., Meyer J., et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 97:2003;1107-1114
13. Aparicio T., Desrame J., Lecomte T., et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br. J. Cancer. 89:2003;1439-1444
14. Sastre J., Marcuello E., Massuti B., et al. CPT-11+48h 5-FU continuous infusion (CI) as first line chemotherapy for elderly patients (pts) with metastatic colorectal cancer (MCRC). Preliminary results of a Spanish digestive (TTD) group study. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1329)
15. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412
16. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:2000;1041-1047
17. Mitry E., Douillard J.Y., Van Cutsem E., et al. Predictive factors of survival in patients with advanced colorectal cancer (ACC). An individual data analysis of 602 patients included in CPT-11 phase III trials (V302 and V303). Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1184)
18. Rougier P., Mitry E., Cunningham D., et al. Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1072)
19. Comella P., Farris A., Lorusso V., et al. Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br. J. Cancer. 89:2003;992-996
20. Maughan T.S., James K.D., Kerr D.J., et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 361:2003;457-464
21. Daniele B., Rosati G., Tambaro R., et al. First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J. Clin. Gastroenterol. 36:2003;228-233
22. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947
23. Wellington K., Goa K.L. Oral tegafur/uracil. Drugs Aging. 18:2001;935-948. discussion 949-950
24. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 19:2001;4097-4106
25. Poole C.A., Gardiner J., Twelves C., et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother. Pharmacol. 49:2002;225-234
26. Twelves C., Glynne-Jones R., Cassidy J., et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. 5:1999;1696-1702
27. Extermann M., Balducci L. Optimizing cancer care in the elderly: progress in geriatric oncology. Cancer Control. 10:2003;440-441
28. Extermann M., Albrand G., Chen H., et al. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol. 21:2003;3214-3219